Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...

Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) results for EYLEA HD (aflibercept) Injection 8 mg in ...

Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, ...

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD).

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...